ASCO 2018 Summary of Presentation May 16, 2018
ASCO: Accepted Presentations Oral presentations DS-8201 Pexidartinib Poster discussions U3-1402 Quizartinib DS-3032 Poster presentations Trial-in-Progress DS-8201 U3-1402 DS-1062
Important and Interesting ADC Presentations DS-8201 Ph1 study (multiple tumor) update Abstract No: 2501 Oral presentation on June 1 st, 2:45 PM – 5:45 PM U3-1402 Ph1 study (breast cancer) update Abstract No: 2512 Poster discussion on June 4 th , 3:00 PM – 4:15 PM Results will be updated at actual presentation 3
ASCO Presentations: DS-8201 DSI Compound Presentation Tumor Type Lead Author Title Session Type Abstract No: 2501 Trastuzumab deruxtecan Session Name: (DS-8201a) in subjects Developmental with HER2-expressing Therapeutics- Clinical DS-8201 Oral HER2-positive Hiroji Iwata solid tumors: Long-term Pharmacology and Presentation solid tumors results of a large phase 1 Experimental Therapeutics study with multiple Date: June 1, 2018 expansion cohorts Time: 2:45 PM – 5:45 PM Location : S406 A phase 2, multicenter, open-label study of Abstract No.: TPS1102 trastuzumab deruxtecan Session Name: Breast DS-8201 Trial-in- HER2-positive (DS-8201a) in subjects Cancer- Metastatic Progress Poster metastatic breast Jose Baselga with HER2-positive, Date: June 2, 2018 Presentation cancer unresectable and/or Time: 8:00 AM – 11:30 metastatic breast cancer AM previously treated with T- Location : Hall A DM1 Abstract No: TPS4133 A randomized, phase 2, Session Name: multicenter, open-label Gastrointestinal Trial-in- HER2-positive Kensei study of trastuzumab (Noncolorectal) Cancer DS-8201 Progress Poster gastric cancer Yamaguchi deruxtecan (DS-8201a) in Date: June 3, 2018 Presentation subjects with HER2- Time: 8:00 AM – 11:30 expressing gastric cancer AM Location : Hall A 4
ASCO Presentations: ADC Franchise DSI Compound Presentation Tumor Type Lead Author Title Session Type Abstract No: 2512 Session Name: Developmental Therapeutics-Clinical Pharmacology and Single Agent Activity of Experimental Therapeutics U3-1402, a HER3- Poster Metastatic breast Takahiro Targeting Antibody-Drug Poster Discussion U3-1402 Discussion cancer Kogawa Conjugate, in Breast Date: June 4, 2018 Cancer Patients: Phase 1 Time: 3:00 PM – 4:15 PM Dose Escalation Study Location : S406 Poster Session Date: June 4, 2018 Time : 8:00 AM – 11:30 AM Location : Hall A Abstract No.: TPS9110 Phase 1 Study of the Session Name: Lung Anti-HER3 Antibody Trial-in- Metastatic or Cancer—Non-Small Cell U3-1402 Drug Conjugate Progress Poster unresectable Pasi A. Jänne Metastatic U3-1402 in Metastatic or Presentation EGFR-mutant Date: June 3, 2018 Unresectable NSCLC Time: 8:00 AM – 11:30 AM EGFR-Mutant NSCLC Location: Hall A Abstract No: TPS2605 Session Name: First-in-human phase 1 Developmental DS-1062 Trial-in- study of DS-1062a in Therapeutics- Clinical Advanced solid Progress Poster Jacob M. Sands patients (pts) with Pharmacology and tumors Presentation advanced solid tumors Experimental Therapeutics (AST) Date: June 4, 2018 Time: 8:00 AM – 11:30 AM Location : Hall A 5
ASCO Presentations: AML Franchise DSI Presentation Tumor Type Lead Author Title Session Compound Type Abstract No.: 7017 Session Name: Hematologic Post hoc exploratory Malignancies-Leukemia, analysis of two phase 2 Myelodysplastic Syndromes, trials of quizartinib and Allotransplant FLT3-ITD- monotherapy in patients mutated (pts) with FLT3-ITD– Poster Discussion Poster Quizartinib relapsed/refracto Mark J. Levis mutated (mu) Date: June 4, 2018 Discussion ry acute myeloid relapsed/refractory (R/R) Time: 11:30 AM – 12:45 PM leukemia (AML) AML with or without prior Location : E450 1st-generation FLT3 tyrosine kinase inhibitors Poster Session (TKI) treatment Date: June 4, 2018 Time : 8:00 AM – 11:30 AM Location : Hall A Abstract No: 11514 Session Name: Sarcoma A phase 1 study of the Poster Discussion MDM2 inhibitor DS-3032b Date: June 2, 2018 Advanced solid Poster in patients with well/de- Time: 3:00 PM – 4:15 PM DS-3032 tumors and Todd M. Bauer Discussion differentiated liposarcoma Location : S404 lymphomas (WD/DD LPS), solid tumors (ST) and lymphomas (L) Poster Session Date: June 2, 2018 Time : 8:00 AM – 11:30 AM Location : Hall A 6
ASCO Presentations: Breakthrough Science DSI Compound Presentation Type Tumor Type Lead Author Title Session Final results of ENLIVEN: a global, Abstract No: double-blind, 11502 randomized, Session Name: Pexidartinib Tenosynovial giant- placebo-controlled, Sarcoma Oral Presentation William D. Tap Date: June 4, 2018 cell tumor (TGCT) Phase 3 study of Time: 8:00 AM – pexidartinib in 11:00 AM advanced Location : S100a tenosynovial giant cell tumor (TGCT) 7
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: DaiichiSankyoIR@daiichisankyo.co.jp
Recommend
More recommend
